Extended Data Fig. 1: Patient evaluation groups.
From: Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Shown is a flow diagram summarizing study enrollment and patient evaluation groups in the MET-exon-14-altered advanced NSCLC expansion cohort of the ongoing PROFILE 1001 study as of 31 January 2018. Patients who received ≥1 dose of crizotinib were included in the safety population and analyses of PFS and OS. OS, overall survival; PFS, progression-free survival.
